MEDICAL ONCOLOGY

CLOSED TO RECRUITMENT — AUSTRALIA

Abbrev. Title

Protocol Title

TROG 17.02 OUTRUN A Randomised Phase II Trial of Osimertinib with or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases

WO29637 IMmotion151 A Phase III, Open-Label, Randomiozed Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Bevacizumab versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma

WO30070 IMvigor130 A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (AntiPD-L1 Antibody) as Monotherapy and in Combination with Platinum-Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma

WO39210 IMmotion010 A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis following Nephrectomy

WO40242 IMvoke010 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients with High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

WO41994 IMmotion250 A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab in Combination with Cabozantinib in Patients with Renal Cell Carcinoma who Experienced Disease Progression During or After Check Point Inhibitor Treatment

XL184-312 COSMIC 312 A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma who Have Not Received Previous Systemic Anticancer Therapy

XL184-313 COSMIC-313 A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk

XL184-401 COSMIC-401 A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/day compared to 140 mg/day in Progressive, Metastatic Medullary Thyroid Cancer Patients

XNW7201-1-02 A Phase I, Open-Label, Multi-Center, Non-Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects with Advanced Solid Tumours